Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output

Fluid balance, glomerular filtration rate, and urine output in dogs anesthetized for an orthopedic surgical procedure

(2010) Pedro Boscan et al.   AMERICAN JOURNAL OF VETERINARY RESEARCH

The cellular mechanisms underlying the inhibitory effects of isoflurane and sevoflurane on arginine vasopressin-induced vasoconstriction

(2010) Manabu Shimogai et al.   Journal of Anesthesia

Aquaporins in kidney pathophysiology

(2010) Yumi Noda et al.   Nature Reviews Nephrology

Combretastatin-induced hypertension and the consequences for its combination with other therapies

(2010) Morten Busk et al.   VASCULAR PHARMACOLOGY

Controlled aquaporin-2 expression in the hypertonic environment

(2009) Udo Hasler   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Efficacy of Selected Natural Products as Therapeutic Agents against Cancer⊥

(2008) Sanjeev Banerjee et al.   JOURNAL OF NATURAL PRODUCTS

Serine 269 phosphorylated aquaporin-2 is targeted to the apical membrane of collecting duct principal cells

(2008) Hanne B. Moeller et al.   KIDNEY INTERNATIONAL